News about Global Pharma

Graft Polymer inks manufacturing deal with unnamed Israeli pharma firm

Graft Polymer inks manufacturing deal with unnamed Israeli pharma firm

Global Pharma | 24/08/2023 | By Sudeep Soparkar |  742

Sanyou Biopharmaceuticals and Sinorda Biomedicine signed Strategic Cooperation Agreement

Sanyou Biopharmaceuticals and Sinorda Biomedicine signed Strategic Cooperation Agreement for Advancing Innovative Drug Research and Development<br />

Global Pharma | 23/08/2023 | By Sudeep Soparkar |  496

Korber and Iocto Announce Partnership for the Integration of Pharmaceutical Equipment with Werum PAS-X MES

Körber and Iocto Announce Partnership for the Integration of Pharmaceutical Equipment with Werum PAS-X MES

Global Pharma | 22/08/2023 | By Sudeep Soparkar |  1116

3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling

3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling

Global Pharma | 21/08/2023 | By Sudeep Soparkar |  880

Antheia Appoints Richard Sherwin as Head of Commercialization

Antheia Appoints Richard Sherwin as Head of Commercialization

Global Pharma | 18/08/2023 | By Sudeep Soparkar |  1081

Ascendis Pharma and Phillips-Medisize Receive Third Award for the SKYTROFA Auto-Injector

Ascendis Pharma and Phillips-Medisize Receive Third Award for the SKYTROFA Auto-Injector

Global Pharma | 18/08/2023 | By Sudeep Soparkar |  1469

CPHI Milan to be held at Fiera Milano and Lombardy Pharma Region for 2024

CPHI Milan to be held at Fiera Milano and Lombardy Pharma Region for 2024

Global Pharma | 18/08/2023 | By Sudeep Soparkar |  1115

Hikal Limited Shows Resilient Performance Amid Industry Headwinds

Hikal’s Panolisite undergone US FDA audit which was concluded with ‘Zero’ 483 observations. US FDA approval is in line with de-risking strategy for additional API site to service our global customer base.

Global Pharma | 10/08/2023 | By Manvi |  762

Granules India Q1FY24 Revenue from Operations at INR 9855 mn down 3 Percent YoY

ROCE stood at 9.4 percent and net debt stood at INR 8,569 mn

Global Pharma | 10/08/2023 | By Manvi |  836

IOL Chemicals and Pharmaceuticals Net Profit Grows 32 Percent YoY

The total income for Q1 FY24 stood at INR 570 crore at the same level of INR 570 crore YoY. EBITDA for Q1 FY24 was INR 80 crore as compared to INR 61 crore YoY.

Global Pharma | 10/08/2023 | By Manvi |  721